Skip to main content
. 2021 Nov 5;52(1):29–38. doi: 10.1093/jjco/hyab170

Figure 1.

Figure 1

OS by treatment arm. aStratified by age (18 to <75, ≥75 years) and cytogenetic risk (intermediate, poor). Aza, azacitidine; CI, confidence interval; HR, hazard ratio; NR, not reached; OS, overall survival; Pbo, placebo; Ven, venetoclax.